share_log

Viveon Health Acquisition Corp. and Clearday Inc. Announce Signed Letter of Intent to Merge and Create a Leading Longevity Care Company

Viveon Health Acquisition Corp. and Clearday Inc. Announce Signed Letter of Intent to Merge and Create a Leading Longevity Care Company

Viveon Health Acquisition Corp. 和 Clearday Inc. 宣布签署合并创建领先的长寿护理公司的意向书
GlobeNewswire ·  2023/03/01 07:08

Healthcare and med-tech management teams join forces to accelerate longevity-tech solutions into more than 130 million American lives by 2030.

到2030年,医疗保健和医疗技术管理团队联手将长寿技术解决方案加速进入超过1.3亿美国人的生活。

Norcross, Georgia, and San Antonio, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU), a special purpose acquisition company led by principals experienced in healthcare and med-tech innovation, is pleased to announce that it has identified and entered into a letter of intent with a business combination target company, Clearday (OTCQX: CLRD).

乔治亚州诺克罗斯和德克萨斯州圣安东尼奥,2023年3月1日(GLOBE NEWSWIRE)——由医疗保健和医疗技术创新领域经验丰富的负责人领导的特殊目的收购公司Viveon Health Acquisition Corp(纽约证券交易所美国证券交易所:VHAQ、VHAQU)欣然宣布,它已确定并与业务合并目标公司Clearday(OTD)签订了意向书(OTD CQX: CLRD)。

Clearday provides a technology platform for the aging population that integrates numerous healthcare innovations into personalized, AI-driven care experiences, which continuously assesses an individual's cognitive and physical capabilities.  The company's customized treatment plans are intended to improve the quality of life for aging and special needs populations. With its autonomous companion robotics and innovative care treatments, Clearday intends to address the $1.4 Trillion burden in annual National Health Expenditures for aging adults.   

Clearday 为老龄化人口提供了一个技术平台,该平台将众多医疗保健创新整合到人工智能驱动的个性化护理体验中,持续评估个人的认知和身体能力。该公司的定制治疗计划旨在改善老龄化和特殊需求人群的生活质量。Clearday打算通过其自主伴侣机器人和创新的护理疗法,解决老年人每年1.4万亿美元的国民健康支出负担。

Company Overview

公司概述

Clearday's () mission is to provide industry-leading longevity care that is more accessible and affordable.  Clearday enables aging individuals, those with special needs, and their families, to optimize their quality of life across the healthcare continuum: at home, in community centers, during medical visits, and at full and part-time care facilities. Clearday's Longevity Care Platform seamlessly integrates numerous health technology innovations into personalized AI-driven care experiences.  The platform continuously assesses an individual's cognitive and physical capabilities to deliver a customized plan.

Clearday () 的使命是提供行业领先的、更容易获得和更实惠的长寿护理。Clearday使老年人、有特殊需要的人及其家庭能够在整个医疗保健过程中优化他们的生活质量:在家中、在社区中心、就诊期间以及在全职和兼职护理机构中。Clearday 的长寿护理平台将众多健康技术创新无缝集成到人工智能驱动的个性化护理体验中。该平台持续评估个人的认知和身体能力,以提供定制的计划。

Globally, the population of individuals over the age of 60 is projected to double by 2050, resulting in nearly 2.1 billion people. In 2035, the US Census Bureau predicts that for the first time, there will be more Americans over the age of 65 than those under 18.  These demographics drive the need for new longevity-tech solutions that provide continuous monitoring, increased engagement, and proactive interventions for older individuals.

预计到2050年,全球60岁以上的人口将翻一番,从而达到近21亿人。2035年,美国人口普查局预测,65岁以上的美国人将首次超过18岁以下的美国人。这些人口统计数据推动了对新的长寿技术解决方案的需求,这些解决方案为老年人提供持续监测、提高参与度和积极干预措施。

The Clearday Longevity Care Platform delivers solutions through a hub-n-spoke model involving Clearday at Home, Clearday Labs, Clearday Clubs, Clearday Residential, and Clearday Robotics. Together, they offer the industry's leading proactive engagement, intervention, and monitoring solutions for the aging population.

Clearday 长寿护理平台通过涉及 Clearday at Home、Clearday Labs、Clearday Clubs、Clearday Residential 和 Clearday Robotics 的中心辐射它们共同为老龄化人口提供业界领先的主动参与、干预和监测解决方案。

Management Comments

管理层评论

"Clearday is an ideal merger partner for Viveon Health as it is a transformative healthcare technology company at its inflection point of rapid growth — and addresses an underserved, large, and expanding market," said Jagi Gill, Chief Executive Officer and Chairman of Viveon Health. "As operators ourselves in the healthcare technology space, our hands-on diligence revealed the Clearday team's deliberate expansion and acceleration of their longevity-tech business plan impacting the arc from home to residential care facilities. By leveraging its operational excellence and history in longevity care and bolting on AI-driven solutions to monitor mental and physical health, its solutions can deliver real-time engagement with individuals and their families through robotic-assisted companion care designed to deliver support at any setting. I look forward to working with Jim and the rest of the Clearday team to execute their global sales channel expansion and market development plan poised to deliver growth and shareholder value."

Viveon Health首席执行官兼董事长贾吉·吉尔表示:“Clearday是Viveon Health的理想合并合作伙伴,因为它是一家处于快速增长转折点的变革性医疗技术公司,其目标是服务不足、庞大且不断扩大的市场。”“作为医疗保健技术领域的运营商,我们的亲身调查显示,Clearday团队刻意扩大和加快了长寿科技业务计划,影响了从家庭到寄宿护理机构的范围。通过利用其在长寿护理领域的卓越运营和历史,并借助人工智能驱动的解决方案来监测身心健康,其解决方案可以通过专为在任何环境提供支持的机器人辅助伴侣护理提供与个人及其家庭的实时互动。我期待与吉姆和Clearday团队的其他成员合作,执行他们的全球销售渠道扩张和市场发展计划,以实现增长和股东价值。”

James Walesa, CEO and Founder said, "We are thrilled with the opportunity to partner with Viveon and its industry-leading founders, Drs. Jagi Gill and Rom Papadopoulos. Both have decades of experience scaling healthcare technology businesses. Clearday began seeking partners with operational and financial expertise who shared the vision of Clearday's 'Aging in the Right Place.' It has taken longer than I wanted, but today we found the team that combines capital markets experience with healthcare leadership to accelerate Clearday's mission. Their extensive professional contacts and experience will bolster our sales and go-to-market initiatives and generate additional revenue opportunities for the combined companies."

首席执行官兼创始人詹姆斯·瓦文萨表示:“我们很高兴有机会与Viveon及其行业领先的创始人贾吉·吉尔博士和罗姆·帕帕多普洛斯博士合作。两者都有数十年的扩展医疗技术业务的经验。Clearday开始寻找具有运营和财务专业知识的合作伙伴,他们与Clearday的 “老龄化在正确的地方” 的愿景相同。花了比我想要的更长的时间,但今天我们找到了一支将资本市场经验与医疗保健领导力相结合的团队,以加快Clearday的使命。他们广泛的专业联系和经验将促进我们的销售和市场进入计划,并为合并后的公司创造额外的收入机会。”

Transaction Overview

交易概述

Under the terms of the letter of intent, Clearday's existing equity holders would convert 100% of their equity into the combined public company. The proposed transaction values Clearday at $250 million. Viveon expects to announce additional details regarding the proposed business combination when a definitive merger agreement is executed.

根据意向书的条款,Clearday的现有股权持有人将将其100%的股权转换为合并后的上市公司。拟议的交易估值Clearday为2.5亿美元。Viveon预计将在最终合并协议执行时公布有关拟议业务合并的更多细节。

Completion of a business combination with Clearday is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, satisfaction of the conditions negotiated therein and approval of the transaction by the board and stockholders of both Viveon and Clearday. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all.

除其他事项外,与Clearday的业务合并的完成取决于尽职调查的完成、规定交易的最终协议的谈判、协议中谈判的条件的满足以及Viveon和Clearday董事会和股东对交易的批准。无法保证最终协议会达成,也无法保证拟议的交易将在目前设想的条款或时限内完成,或者根本无法保证。

About Clearday, Inc.

关于 Clearday, Inc.

Clearday is an innovative longevity healthcare technology company with a modern, hopeful vision for making high-quality care solutions more accessible, affordable, and empowering for aging individuals and their families. Clearday has a decades-long experience in non-acute care through its subsidiary Clearday Living, which operates highly-rated residential memory care and adult daycare communities. Its Longevity Care Platform brings Clearday solutions to people wherever they are. Its platform is at the intersection of telehealth, remote monitoring, and patient engagement — all delivered across mobile, wearable, and robotic endpoints in a Software-as-a-Service (SaaS) and Robotics as a Service (RaaS) model. Learn more about Clearday and its pioneering legislative efforts to bring the "Innovative Cognitive Care Act for Veterans" to Congress at .

克利尔迪是一家创新的长寿医疗保健技术公司,其现代而充满希望的愿景是让老年人及其家庭更容易获得、负担得起和增强能力的高质量护理解决方案。Clearday通过其子公司Clearday Living在非急性护理领域拥有数十年的经验,该公司经营备受好评的寄宿记忆护理和成人日托社区。无论人们身在何处,其长寿护理平台都能为他们提供Clearday解决方案。其平台处于远程医疗、远程监控和患者参与的交叉点——所有这些都以软件即服务 (SaaS) 和机器人即服务 (RaaS) 模式通过移动、可穿戴设备和机器人终端交付。要详细了解Clearday及其为将 “退伍军人创新认知保健法案” 提交国会而做出的开创性立法工作,请访问。

About Viveon Health Acquisition Corp.

关于 Viveon Health 收购公司

Viveon Health Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It is the Company's intention to pursue prospective targets that are focused on the healthcare sector in the United States and other developed countries.

Viveon Health Acquisition Corp. 是一家空白支票公司,通常也被称为特殊目的收购公司或SPAC,其成立的目的是与一家或多家企业进行合并、股份交换、资产收购、股份购买、重组或类似的业务合并。该公司打算追求以美国和其他发达国家的医疗保健行业为重点的预期目标。

No Offer or Solicitation

不得提出要约或邀请

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

本新闻稿不构成就任何证券或拟议的业务合并征求委托人、同意或授权。本新闻稿也不构成任何证券的出售要约或征求购买任何证券的要约,也不得在根据任何此类司法管辖区的证券法进行注册或资格认证的任何州或司法管辖区出售证券。除非通过符合经修订的1933年《证券法》第10条要求的招股说明书或该招股说明书的豁免,否则不得发行证券。

Forward-Looking Statements

前瞻性陈述

Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "target," "believe," "expect," "will," "shall," "may," "anticipate," "estimate," "would," "positioned," "future," "forecast," "intend," "plan," "project," "outlook" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters.  These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Viveon's ability to enter into a definitive agreement or consummate a transaction with the target company. These statements are based on various assumptions and on the current expectations of Viveon's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Viveon and the target company. These forward-looking statements are subject to a number of risks and uncertainties, including: Viveon's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction with the target company; the risk that the approval of the stockholders of Viveon for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction; the amount of redemption requests made by Viveon's stockholders and the amount of funds remaining in Viveon's trust account after satisfaction of such requests; those factors discussed in Viveon's prospectus for its initial public offering dated December 28, 2020, under the heading "Risk Factors," and other documents of Viveon filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Viveon presently does not know or that Viveon currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Viveon's expectations, plans or forecasts of future events and views as of the date hereof. Viveon anticipates that subsequent events and developments will cause Viveon's assessments to change. However, while Viveon may elect to update these forward-looking statements at some point in the future, Viveon specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Viveon's assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

本新闻稿中的某些陈述是1995年《私人证券诉讼改革法》“安全港” 条款所指的 “前瞻性陈述”。前瞻性陈述可以通过使用 “目标”、“相信”、“期望”、“将”、“应该”、“可能”、“预期”、“估计”、“将”、“定位”、“未来”、“预测”、“打算”、“计划”、“项目”、“展望” 等词语来识别,这些表达方式预测或表明未来事件或趋势或不是历史问题陈述。这些前瞻性陈述包括但不限于有关收入的预测、估计和预测以及其他财务和业绩指标的陈述,以及对市场机会和预期的预测,Viveon与目标公司签订最终协议或完成交易的能力。这些陈述基于各种假设和Viveon管理层当前的预期,而不是对实际业绩的预测。这些前瞻性陈述仅用于说明目的,无意用作担保、保证、预测或明确的事实或概率陈述,也不得被任何投资者作为担保、保证、预测或明确的事实或概率陈述。实际事件和情况很难或不可能预测,并且会与假设有所不同。许多实际事件和情况是Viveon和目标公司无法控制的。这些前瞻性陈述受许多风险和不确定性的影响,包括:Viveon能否就拟议的业务合并达成最终协议或与目标公司完成交易;潜在交易未获得Viveon股东批准的风险;未能实现潜在交易的预期收益,包括潜在交易延迟完成所致;赎回申请金额由 Viveon 的股东制作以及满足此类请求后Viveon信托账户中剩余的资金金额;Viveon在2020年12月28日标题为 “风险因素” 的首次公开募股招股说明书以及Viveon向美国证券交易委员会提交或将要提交的其他文件中讨论的因素。如果风险出现或假设被证明不正确,则实际结果可能与这些前瞻性陈述所暗示的结果存在重大差异。可能还有其他风险是Viveon目前不知道的,或者是Viveon目前认为不重要的风险,这些风险也可能导致实际结果与前瞻性陈述中包含的结果不同。此外,前瞻性陈述反映了截至本文发布之日Viveon对未来事件和观点的预期、计划或预测。Viveon预计,随后的事件和事态发展将导致Viveon的评估发生变化。但是,尽管Viveon可能会选择在未来的某个时候更新这些前瞻性陈述,但Viveon明确表示不承担任何这样做的义务。截至本新闻稿发布之日之后的任何日期,均不应依赖这些前瞻性陈述来代表Viveon的评估。因此,不应过分依赖前瞻性陈述。

Contact:

联系人:

Rom Papadopoulos
Viveon Health Acquisition Corp.
Chief Financial Officer
rom@viveonhealth.com
404-861-0839

罗姆·帕帕多普洛斯
Viveon Health 收购公司
首席财务官
rom@viveonhealth.com
404-861-0839

Ginny Connolly
Clearday Inc.
Investor Relations
info@myclearday.com
210-451-0839

金妮康诺利
Clearday Inc.
投资者关系
info@myclearday.com
210-451-0839


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发